4-phenyl-1-oxa-4,9-diazaspiro-[5,5]-undecan-3-one | 85151-19-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-phenyl-1-oxa-4,9-diazaspiro-[5,5]-undecan-3-one
• 英文别名: 4-Phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
• CAS: 85151-19-5
• 化学式: C₁₄H₁₈N₂O₂
• 分子量: 246.309
• InChiKey: VTEFXRILODGPKL-UHFFFAOYSA-N

物化性质

• 沸点：
  484.1±45.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3-(piperidin-1-yl)propoxy)benzoyl chloride 、 4-phenyl-1-oxa-4,9-diazaspiro-[5,5]-undecan-3-one 在 三乙胺 、 盐酸 作用下， 以 二氯甲烷 、 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 4-phenyl-9-[4-(3-piperidin-1-ylpropoxy)benzoyl]-1-oxa-4,9-diazaspiro-[5, 5]-undecan-3-one hydrochloride
  参考文献：
  名称：

  [EN] ARYLOXYALKYLAMINE DERIVATES AS H3 RECEPTOR LIGANDS
  [FR] DERIVES D'ARYLOXYALKYLAMINE TELS QUE DES LIGANDS DU RECEPTEUR H3

  摘要：

  本发明涉及具有药理活性的新型苄氧基衍生物，其制备方法，含有它们的组合物以及它们在治疗神经系统和精神疾病中的用途。

  公开号：

  WO2004037800A1
• 作为产物：
  描述：

  3-Oxo-4-phenyl-1-oxa-4,9-diaza-spiro[5.5]undecane-9-carboxylic acid benzyl ester 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 4-phenyl-1-oxa-4,9-diazaspiro-[5,5]-undecan-3-one
  参考文献：
  名称：

  Antihypertensive 9-substituted 1-0xa-4,9-diazaspiro[5.5]undecan-3-ones

  摘要：

  Forty-one 9-substituted 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones were prepared for antihypertensive screening in the spontaneously hypertensive rat (SHR). For the 9-(2-indol-3-ylethyl) series, the parent compound, 9-(2-indol-3-ylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (21), was the most potent antihypertensive agent. Substitution of lower alkyl groups on the spirolactam ring gave compounds close in activity to 21, while substitution with large alkyl or aryl groups led to a significant decrease in activity. Ring-opened analogues of 21 that contained the same functionality were markedly less active. Several 1-oxa-4,9-diazaspiro[5.5]undecan-3-ones substituted at the 9 position with 1,4-benzodioxan-2-ylmethyl, 1,4-benzodioxan-2-ylhydroxyethyl, and 2-phenylethyl groups also demonstrated significant activity. Compound 21 was chosen for a detailed pharmacological evaluation. Its antihypertensive activity appears to be predominantly due to peripheral alpha 1-adrenoceptor blockade.

  DOI：

  10.1021/jm00360a013

文献信息

• SPIRO COMPOUND AND USE THEREOF
  申请人：Taniguchi Takahiko

  公开号：US20100069351A1

  公开（公告）日：2010-03-18

  The present invention aims to provide a novel SCD inhibitor. The present invention relate to SCD inhibitor comprising A compound represented by the formula (I) wherein R is an optionally substituted cyclic group or an optionally substituted carbamoyl group, provided that R is not an optionally substituted 7-pyrido[2,3-d]pyrimidyl group; ring A is an optionally further substituted pyridazine ring; R 1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 13 and R 14 are each independently a hydrogen atom or a substituent, or R 1 and R 11 in combination, R 2 and R 12 in combination, R 3 and R 13 in combination, or R 4 and R 14 in combination optionally form an oxo group, or R 2 and R 4 in combination optionally form a bond or an alkylene cross-linkage; m and n are each independently an integer of 0 to 2; ring B is an optionally substituted ring, provided that the two atoms constituting ring B, which are adjacent to the spiro carbon atom, are not oxygen atoms at the same time, or a salt thereof, or a prodrug thereof.

  本发明旨在提供一种新型SCD抑制剂。本发明涉及一种包括下式（I）所表示的化合物的SCD抑制剂：其中R是一个可选择取代的环基或可选择取代的氨甲酰基，但R不是一个可选择取代的7-吡啶并[2,3-d]嘧啶基团；环A是一个可选择进一步取代的吡啶并嘧啶环；R1、R2、R3、R4、R11、R12、R13和R14分别独立地是氢原子或取代基，或R1和R11的组合体，R2和R12的组合体，R3和R13的组合体，或R4和R14的组合体可选择形成氧基，或R2和R4的组合体可选择形成键或烷基交联；m和n分别独立地是0到2的整数；环B是一个可选择取代的环，但构成环B的两个与螺碳原子相邻的原子不同时为氧原子，或其盐，或其前药。
• Aryloxyalkylamine derivatives as h3 receptor ligands
  申请人：Best John Desmond

  公开号：US20060052597A1

  公开（公告）日：2006-03-09

  The present invention relates to novel benzyloxy derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型苯甲氧基衍生物，其制备过程，包含它们的组合物以及它们在治疗神经病学和精神病学疾病中的应用。
• Spiro compounds having stearoyl-CoA desaturase action
  申请人：Taniguchi Takahiko

  公开号：US08575167B2

  公开（公告）日：2013-11-05

  The present invention aims to provide a novel SCD inhibitor. The present invention relate to SCD inhibitor comprising A compound represented by the formula (I) wherein R is an optionally substituted cyclic group or an optionally substituted carbamoyl group, provided that R is not an optionally substituted 7-pyrido[2,3-d]pyrimidyl group; ring A is an optionally further substituted pyridazine ring; R1, R2, R3, R4, R11, R12, R13 and R14 are each independently a hydrogen atom or a substituent, or R1 and R11 in combination, R2 and R12 in combination, R3 and R13 in combination, or R4 and R14 in combination optionally form an oxo group, or R2 and R4 in combination optionally form a bond or an alkylene cross-linkage; m and n are each independently an integer of 0 to 2; ring B is an optionally substituted ring, provided that the two atoms constituting ring B, which are adjacent to the spiro carbon atom, are not oxygen atoms at the same time, or a salt thereof, or a prodrug thereof.

  本发明旨在提供一种新型SCD抑制剂。本发明涉及一种包括式(I)所表示的化合物的SCD抑制剂，其中R是一个可选取的取代环基团或可选取的取代的氨基甲酰基基团，但R不能是一个可选取的取代的7-吡啶并[2,3-d]嘧啶基团；环A是一个可选取的进一步取代的吡啶并咪唑环；R1、R2、R3、R4、R11、R12、R13和R14各自独立地是氢原子或取代基，或者R1和R11组合、R2和R12组合、R3和R13组合、或R4和R14组合可以选择形成一个氧代基，或R2和R4组合可以选择形成一个键或一个烷基交联；m和n各自独立地是0到2的整数；环B是一个可选取的取代环，但构成环B的两个相邻于螺碳原子的原子不同时为氧原子；或其盐或前药。
• Novel Piperidine Derivative
  申请人：Ishikawa Shiho

  公开号：US20090137576A1

  公开（公告）日：2009-05-28

  Disclosed is a substance having an antagonistic effect on the binding of histamine to a histamine H3 receptor or an inhibitory effect on the activity which a histamine H3 receptor constantly exhibits. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 represents a phenyl group which may be substituted or the like and R2 represents a cyano group which may be substituted or the like, or R1 and R2 together form an aliphatic heterocylic ring which may be substituted; R3 represents a group represented by the formula (II-1) below; and all of X1 to X4 represent a carbon atom or the like: (II-1) where R4 and R5 represent a lower alkyl group or the like; and m1 represents an integer of 2 to 4.

  本发明涉及一种物质，其对组胺与组胺H3受体的结合具有拮抗作用，或对组胺H3受体不断表现的活性具有抑制作用。化合物由式(I)或其药学上可接受的盐表示；(I)其中R1代表可能被取代或类似的苯基团，R2代表可能被取代或类似的氰基团，或R1和R2一起形成可能被取代的脂肪族杂环环；R3代表由下式(II-1)表示的基团；X1到X4都表示碳原子或类似物：(II-1)其中R4和R5代表较低的烷基团或类似物；m1表示2到4的整数。
• NOVEL PIPERIDINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1892241A1

  公开（公告）日：2008-02-27

  Disclosed is a substance having an antagonistic effect on the binding of histamine to a histamine H3 receptor or an inhibitory effect on the activity which a histamine H3 receptor constantly exhibits. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 represents a phenyl group which may be substituted or the like and R2 represents a cyano group which may be substituted or the like, or R1 and R2 together form an aliphatic heterocylic ring which may be substituted; R3 represents a group represented by the formula (II-1) below; and all of X1 to X4 represent a carbon atom or the like: (II-1) where R4 and R5 represent a lower alkyl group or the like; and ml represents an integer of 2 to 4.

  本发明公开了一种对组胺与组胺 H3 受体的结合具有拮抗作用或对组胺 H3 受体持续表现出的活性具有抑制作用的物质。由式(I)代表的化合物或其药学上可接受的盐； (I) 其中 R1 代表可被取代的苯基或类似基团，R2 代表可被取代的氰基或类似基团，或 R1 和 R2 共同形成可被取代的脂族杂环；R3 代表下式(II-1)所代表的基团； 且所有 X1 至 X4 均代表碳原子或类似物：(II-1) 其中 R4 和 R5 代表低级烷基或类似基团；ml 代表 2 至 4 的整数。